glp 1 compound ending Patients struggle as compounded GLP-1 access rapidly shrinks 🚨 FDA Moves to Permanently

A.BanksW

Kapantais et al

Arkin, M

This approach may appeal to patients who: prefer branded therapy first want compounded medication only as a backup during shortage disruption are uncomfortable using a provider whose business model depends heavily on compounding Mochi Healths Position Mochi is much more directly exposed to the compounding conversation because affordable compounded access is core to its value proposition

Changes from baseline in cardiovascular, metabolic, and inflammatory biomarkers among GLP-1 drug users were as follows: Triglycerides: -16.4 mg/dL LDL cholesterol: -7.3 mg/dL HbA1c: -0.3 percentage points CRP: -0.6 mg/dL ESR: -3.0 mm/hr These were all numerically greater than corresponding changes for non-users, but often the differences didn't reach statistical significance

B7 (Biotin) Biotin is well known for supporting healthy hair, skin, and nails